These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25531398)

  • 1. Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.
    Nelson LM; Gustafsson F; Gimsing P
    Acta Haematol; 2015; 133(4):336-46. PubMed ID: 25531398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
    Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
    Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
    Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
    Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current treatment of AL amyloidosis].
    Kovacsovics T
    Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
    Warsame R; Bang SM; Kumar SK; Gertz MA; Lacy MQ; Buadi F; Dingli D; Hayman SR; Kapoor P; Kyle RA; Leung N; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Rajkumar SV; Dispenzieri A
    Eur J Haematol; 2014 Jun; 92(6):485-90. PubMed ID: 24502602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
    Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
    Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece.
    Michael M; Kastritis E; Delimpassi S; Michalis E; Repoussis P; Kyrtsonis MC; Katodritou E; Anagnostopoulos N; Zervas K; Dimopoulos MA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):56-61. PubMed ID: 20223730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
    Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
    Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
    Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L
    Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
    D'Souza A; Dispenzieri A; Wirk B; Zhang MJ; Huang J; Gertz MA; Kyle RA; Kumar S; Comenzo RL; Peter Gale R; Lazarus HM; Savani BN; Cornell RF; Weiss BM; Vogl DT; Freytes CO; Scott EC; Landau HJ; Moreb JS; Costa LJ; Ramanathan M; Callander NS; Kamble RT; Olsson RF; Ganguly S; Nishihori T; Kindwall-Keller TL; Wood WA; Mark TM; Hari P
    J Clin Oncol; 2015 Nov; 33(32):3741-9. PubMed ID: 26371138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.